Dizal Demonstrates Clinical Update for Sunvozertinib (DZD9008) in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 WCLC

SHANGHAI, Aug. 5, 2022 /PRNewswire/ -- Dizal presented positive clinical updates highlighting the therapeutic potential of sunvozertinib in non-small cell lung cancer (NSCLC) with epidermal growth factor receptor exon 20 insertion (EGFR Exon20ins) mutation at 2022 World Conference on Lung Cancer (WCLC).

Lung cancer is the second most common cancer and leading cause of cancer death globally.1 NSCLC accounts for approximately 85% of all lung cancers. NSCLC patients with EGFR Exon20ins mutation lack effective treatment options.

Sunvozertinib, which was granted Breakthrough Therapy Designation by US FDA and China NMPA, is a rationally designed, oral, potent EGFR Exon20ins inhibitor, with wild-type EGFR selectivity. It is currently being evaluated in late-stage development of multiple global pivotal studies as ≥ 2nd line treatment after platinum-based chemotherapy and 1st line treatment for treatment-naïve patients.

Updated findings from the studies were presented at 2022 WCLC. As of April 30, 2022, in platinum-pretreated patients (n=119), the best ORR (at the RP2D of 300mg QD) assessment according to RECIST guidelines (version 1.1) was 52.4%. In patients with baseline brain metastasis, the best ORR at 300 mg QD reached 44%. The safety profile of sunvozertinib was amenable to long-term treatment. The most common drug related TEAE (treatment emergent adverse event) were diarrhea and rash, the majority of which were Grade 1/2 and clinically manageable.

"We are excited to share these updated findings to peer clinicians, researchers and scientists at WCLC." said Dr. Xiaolin Zhang, CEO of Dizal, "With its superior antitumor efficacy and favorable safety, we are confident that sunvozertinib has the potential to become a best-in-class treatment option for NSCLC patients harboring EGFR Exon20ins mutation with persisting unmet medical need."

About Dizal

Dizal is a clinical-stage, biopharmaceutical company, dedicated to the discovery and development of differentiated therapeutics for the treatment of cancer and immunological diseases. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio of five clinical-stage assets with two leading assets in global pivotal studies.

About WCLC

The World Conference on Lung Cancer is the world's largest multidisciplinary oncology conference dedicated to lung cancer and other thoracic malignancies. The 2022 annual meeting will be held in Vienna, Austria, online and offline, from August 6-9, hosted by the International Association for the Study of Lung Cancer (IASLC). Founded in 1974, IASLC is a global organization in the field of lung cancer. It is committed to the research on the etiology, epidemiology, prevention, diagnosis and treatment of lung cancer and other thoracic malignancies, providing the most cutting-edge innovative ideas and scientific research results in eliminating the threat to human health of lung cancer and other thoracic malignancies.

Forward-Looking Statements

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", and "intend" and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal's competitive environment, and political, economic, legal, and social conditions.

Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turn out to be incorrect. 


  1. https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html


View original content:https://www.prnewswire.com/news-releases/dizal-demonstrates-clinical-update-for-sunvozertinib-dzd9008-in-platinum-pretreated-nsclc-patients-with-egfr-exon20ins-mutations-at-2022-wclc-301600601.html

SOURCE Dizal Pharmaceutical

Posted In: trade showsPress Releases